- 24 h
- letzte 200 News
| Zeit | Aktuelle Nachrichten | ||
|---|---|---|---|
| 13:46 | Casgevy gains UK label expansion for younger patient population | ||
| 12:47 | Eli Lilly's tirzepatide outperforms big pharma companies in Q3 | ||
| 11:47 | Glenmark opens Allentown distribution hub in US | ||
| 10:46 | Dren Bio raises $350m for dibotatug clinical development | ||
| Do | RFK Jr backs compounding of six unapproved peptides in new policy | ||
| Do | UK Budget light on life sciences but more doors open for biotech startups | ||
| Do | Enthorin and Rumi sign agreement for FXS therapy | ||
| Do | Formation Bio launches $600m drug development fund | ||
| Mi | Ferring bets on Gameto's reproductive health solution through $1.38bn takeover | ||
| Mi | Astellas fortifies immuno-oncology pipeline on $1.3bn Audax licensing deal | ||
| Mi | FDA grants orphan drug status to Octant's OCT-980 for RP | ||
| Mi | Arrowhead gains UK marketing authorisation for Redemplo | ||
| Mi | Anthropic plots IPO amid ongoing foray into drug development | ||
| Di | Pfizer's prostate cancer combo moves to earlier line on expanded US approval | ||
| Di | Regeneron agrees to $270m extension to supply Ebola medicine in US | ||
| Di | China's NMPA accepts Innovent application for sintilimab combo | ||
| Mo | UK biotech poised for record VC year after maintaining recovery momentum | ||
| Mo | Lunit and Summit to evaluate pathology platform for tumour analysis | ||
| Mo | Pathos AI completes $237m Series E round to expand oncology pipeline | ||
| 23.10. | US targets Chinese biotech investment, but licensing deals remain exempt | ||
| 23.10. | Gilead spends $1.28bn on PepStar's potential Icotyde rival | ||
| 23.10. | Boehringer and Microsoft collaborate to explore AI in clinical research | ||
| 23.10. | Celltrion and Kaigene sign $580m licence deal for KG013 | ||
| 22.10. | Roche's pharma sales grow 7% but pipeline trimmed down | ||
| 22.10. | AstraZeneca bags another US indication for Ultomiris with IgAN approval |
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und sowie Kurse und Daten von ARIVA.DE AG.